The offering was priced at a steep 27.6% discount to the prior close, indicating aggressive demand absorption. Monitor for potential further dilution from the $150M ATM facility still available and the 8.1M outstanding warrants. The REGAL trial topline success may support the stock, but the large discount and frequent capital raises (6 offerings in 24 months) signal ongoing cash needs.
Drugs in focus
SLS drug pipeline →galinpepimut-S
● Neutral Named in this 424B5- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 REGAL trial succeeds, the earliest potential regulatory submission (BLA) would follow the topline readout in Q4 2026, with an FDA review timeline of roughly 10-12 months thereafter, putting a potential approval in late 2027 or early 2028 at the earliest.
- Next catalyst
- None dated
What to watchWatch for the topline Phase 3 REGAL overall survival readout, expected within the next two months (Q4 2026). A positive result showing statistically significant survival benefit could drive the stock toward analyst targets of $30-$35, while a miss or marginal result would likely devastate the stock given the company's pre-revenue status and dependence on this single asset. The ongoing securities investigation adds a secondary legal risk to monitor.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SELLAS Life Sciences Group priced a $150M underwritten public offering of 11,538,462 shares at $13.00 per share, a 27.6% discount to the prior day's $17.95 close. The offering follows positive Phase 3 REGAL trial results announced November 17, 2026 and Q3 2026 earnings reported November 12, 2026. Net proceeds of approximately $140.6M will fund clinical development and commercialization activities.
Key Financial Metrics
Key Facts
- 11,538,462 shares offered at $13.00 per share, a 27.6% discount to the $17.95 closing price on November 18, 2026
- Total offering size of $150,000,006; net proceeds of approximately $140.6M ($161.8M if underwriters exercise full option)
- Underwriters have a 30-day option to purchase up to an additional 1,730,769 shares
- Shares outstanding will increase from 203,527,833 to 215,066,295 (5.7% dilution), or 216,797,064 if option exercised (6.5% dilution)
- Lead underwriters: J.P. Morgan, TD Cowen, Mizuho, A.G.P., Maxim Group LLC
- 60-day lock-up for company and insiders
- Filing follows positive Phase 3 REGAL trial data (November 17, 2026) and Q3 2026 earnings (November 12, 2026)
Financial Impact
$150M gross offering at $13.00/share, net proceeds ~$140.6M; 5.7% dilution to existing shares
Risk Factors
- Significant discount to market price may pressure the stock near term
- Additional $150M ATM facility remains available, creating further overhang
- 8.1M warrants and other equity awards could add further dilution
- Company has raised capital frequently (6 offerings in 24 months), suggesting high cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-130132 |
| Document: tm2629996d2_exfilingfees.htm | 0001104659-26-130132 |
| Document: 0001104659-26-130132-index-headers.html | 0001104659-26-130132 |
| Document: 0001104659-26-130132-index.html | 0001104659-26-130132 |
| Document: 0001104659-26-130132.txt | 0001104659-26-130132 |
Track record
19 reports on SLS
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +63.62% at T+60 after the Mar 12, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 20, 20262d ago 8-K Bearish 6/10 Entry $14.80 Now $13.66 +7.70% settles Nov 23
- Nov 19, 20262d ago 424B5 Bearish 6/10 Viewing Entry $14.86 Now $13.66 +8.08% settles Nov 23
- Nov 18, 20263d ago Press Release Bearish 6/10 Entry $14.86 to $13.66 Now $13.66 +8.08% ▲ +8.08% +4.43% vs SPY
- Nov 17, 20264d ago 424B5 Bearish 6/10 Entry $17.95 to $14.86 Now $13.66 +23.90% ▲ +17.21% +15.25% vs SPY
- Nov 17, 20264d ago Press Release Bearish 6/10 Entry $17.95 to $14.86 Now $13.66 +23.90% ▲ +17.21% +15.25% vs SPY
- Nov 17, 20264d ago 8-K Bullish 7/10 Entry $19.15 to $17.95 Now $13.66 −28.67% ▼ −6.27% −5.96% vs SPY
- Nov 17, 20265d ago Press Release Bullish 8/10 Entry $19.15 to $17.95 Now $13.66 −28.67% ▼ −6.27% −5.96% vs SPY
- Nov 12, 20269d ago 8-K Neutral 5/10 Entry $7.86 to $7.47 Now $13.66 +73.79% ▼ −4.96% −3.05% vs SPY
- Nov 10, 202611d ago SC 13G Neutral 3/10 Entry $8.37 to $8.42 Now $13.66 +63.20% ▲ +0.60% −0.72% vs SPY
- Nov 3, 202618d ago Institutional Cluster Neutral 3/10 Entry $8.87 to $9.14 Now $13.66 +54.00% ▲ +3.04% +1.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers